Pharmaron Beijing Co., Ltd.

SZSE:300759 Stock Report

Market Cap: CN¥46.3b

Pharmaron Beijing Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Boliang Lou

Chief executive officer

CN¥2.2m

Total compensation

CEO salary percentagen/a
CEO tenure9.4yrs
CEO ownershipn/a
Management average tenure9.4yrs
Board average tenure8.9yrs

Recent management updates

Recent updates

Why Pharmaron Beijing Co., Ltd. (SZSE:300759) Could Be Worth Watching

Mar 17
Why Pharmaron Beijing Co., Ltd. (SZSE:300759) Could Be Worth Watching

CEO Compensation Analysis

How has Boliang Lou's remuneration changed compared to Pharmaron Beijing's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

CN¥2b

Jun 30 2025n/an/a

CN¥1b

Mar 31 2025n/an/a

CN¥2b

Dec 31 2024CN¥2mn/a

CN¥2b

Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥1b

Dec 31 2023CN¥2mCN¥2m

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥2b

Mar 31 2023n/an/a

CN¥1b

Jan 01 2023n/an/a

CN¥1b

Sep 30 2022n/an/a

CN¥2b

Jun 30 2022n/an/a

CN¥2b

Mar 31 2022n/an/a

CN¥2b

Dec 31 2021CN¥8mCN¥2m

CN¥2b

Sep 30 2021n/an/a

CN¥1b

Jun 30 2021n/an/a

CN¥1b

Mar 31 2021n/an/a

CN¥1b

Dec 31 2020CN¥4mCN¥2m

CN¥1b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥865m

Mar 31 2020n/an/a

CN¥594m

Dec 31 2019CN¥3mCN¥2m

CN¥547m

Compensation vs Market: Boliang's total compensation ($USD320.50K) is above average for companies of similar size in the CN market ($USD230.86K).

Compensation vs Earnings: Boliang's compensation has been consistent with company performance over the past year.

CEO

Boliang Lou (62 yo)

9.4yrs
Tenure
CN¥2,213,300
Compensation

Dr. Boliang Lou, Ph D serves as Chairman of the Board and Chief Executive Officer at Pharmaron, Inc. He is a Co-Founder at Pharmaron, Inc. Dr. Lou serves as the Chairman, Chief Executive Officer and Manage...

Leadership Team

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEOno dataCN¥2.21mno data
Xiaoqiang Lou
Co-Founder9.4yrsCN¥1.91m5.5%
CN¥ 2.5b
Shing Chung Li
CFO, Secretary of the Board & Employee Representative Directorno dataCN¥1.99mno data
Hua Yang
Chief Scientific Officer & Deputy Manager9.4yrsCN¥1.91mno data
Bei Zheng
Executive VP & Executive Director9.4yrsCN¥1.60m2.06%
CN¥ 954.3m
Connie Sun
Senior VP & Global Head of Business Development of Small Moleculesno datano datano data
Celina Zhong
Senior Vice President of Human Resourcesno datano datano data
Katherine Lee
Chief Business Officer15.2yrsno datano data
Stephen Lewinton
Senior Vice President of UK Operationsno datano datano data
Jingqi Huang
Senior Vice President of In Vivo Pharmacologyno datano datano data
Mandy Xu
Senior Vice President of DMPK4.3yrsno datano data
Sid Bhoopathy
Senior VP and US Head of Laboratory Services & CGT4.3yrsno datano data
9.4yrs
Average Tenure
58yo
Average Age

Experienced Management: 300759's management team is seasoned and experienced (9.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Boliang Lou
Chairman & CEO9.4yrsCN¥2.21mno data
Xiaoqiang Lou
Co-Founder9.4yrsCN¥1.91m5.5%
CN¥ 2.5b
Shing Chung Li
CFO, Secretary of the Board & Employee Representative Directorless than a yearCN¥1.99mno data
Bei Zheng
Executive VP & Executive Director9.4yrsCN¥1.60m2.06%
CN¥ 954.3m
Kwan-Hung Tsang
Independent Non Executive Director6.6yrsCN¥300.00kno data
Kexin Yang
Chairman of the Supervisory Board9.4yrsno datano data
Jiaqing Li
Non Executive Director9.4yrsno datano data
Baifeng Hu
Non Executive Director8.4yrsno datano data
Lan Zhang
Employee Representative Supervisor9.4yrsno datano data
Lihua Li
Independent Non Executive Director3.5yrsCN¥300.00k0.0041%
CN¥ 1.9m
Jian Yu
Independent Non Executive Director5.7yrsCN¥300.00kno data
Shu Feng
Supervisor5.3yrsno datano data
8.9yrs
Average Tenure
54.5yo
Average Age

Experienced Board: 300759's board of directors are considered experienced (8.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/06 14:40
End of Day Share Price 2026/03/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmaron Beijing Co., Ltd. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Jin ZhangChina International Capital Corporation Limited